2012 highlights in translational 'omics
Charles Auffray, Timothy Caulfield, Muin J. Khoury, James R. Lupski, Matthias Schwab, Timothy D. Veenstra
Abstract
Open-access reader
Charles Auffray, Timothy Caulfield, Muin J. Khoury, James R. Lupski, Matthias Schwab, Timothy D. Veenstra
Abstract
Open-access reader
This annual editorial from Genome Medicine’s Section Editors highlights the most exciting research from the past year and the potential of these advances for medicine. Last year, we noted that medical ‘omics continued its inexorable move towards the clinic; in 2012 it has truly arrived. DNA capture technologies and sequencing continue to lead the way, with implications for human genomics, personalized medicine, pharmacogenomics and drug labeling, public health screening, and public policy already apparent. There have also been technological advances in proteomics and other ‘omic approaches, and in the integration of these approaches to provide more informative molecular signatures of health and susceptibility to disease. De novo mutations: from complexity to the clinic
OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
This annual editorial from Genome Medicine’s Section Editors highlights the most exciting research from the past year and the potential of these advances for medicine. Last year, we noted that medical ‘omics continued its inexorable move towards the clinic; in 2012 it has truly arrived. DNA capture technologies and sequencing continue to lead the way, with implications for human genomics, personalized medicine, pharmacogenomics and drug labeling, public health screening, and public policy already apparent. There have also been technological advances in proteomics and other ‘omic approaches, and in the integration of these approaches to provide more informative molecular signatures of health and susceptibility to disease. De novo mutations: from complexity to the clinic
Key concepts: Pharmacogenomics, Personalized medicine, Translational medicine, Proteomics, Omics, Human genetics, Genomics, Medicine